Click on right here for a transcript of the episode.
Medicare officers have preliminarily determined to limit reimbursement for Aduhelm, the controversial Alzheimer’s drug, to solely sufferers taking part in authorized medical trials. The FDA authorized the drug in 2021 over objections of the company’s outdoors advisers, who complained the proof of Aduhelm’s efficacy is skinny. However the prospect of huge use of the drug — initially priced at $56,000 a yr — helped immediate the largest-ever improve in Medicare Half B premiums. Now the Division of Well being and Human Companies is whether or not it may well cut back that improve earlier than 2023.
In the meantime, covid confusion continues, because the Biden administration belatedly seeks to develop testing and the supply of higher-quality masks, and the Supreme Courtroom delays an emergency resolution on the administration’s guidelines on vaccine necessities for employees.
This week’s panelists are Julie Rovner of KHN, Joanne Kenen of Politico and the Johns Hopkins Bloomberg College of Public Well being, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat.
Among the many takeaways from this week’s episode:
- The look ahead to a Supreme Courtroom resolution on whether or not President Joe Biden’s plan to mandate vaccinations of all well being care employees and require vaccines or testing of these employed by most large companies is including extra confusion to the chaos surrounding the pandemic proper now. Already there are complaints that recommendation on testing shouldn’t be clear, that federal officers are break up of their suggestions on quarantines, and that statistics on the variety of circumstances and hospitalizations are inaccurate.
- Biden has introduced that non-public insurance coverage corporations will reimburse sufferers for as much as eight at-home exams a month for people who need them. However one large group neglected of that directive are Medicare beneficiaries. Regardless of the apparent want for exams on this susceptible inhabitants, that omission could also be due to strict federal legal guidelines on what may be offered to beneficiaries.
- Advocacy teams and public well being specialists are pressuring the federal authorities to supply higher steering to the general public about what are the perfect masks to make use of. Many individuals have switched from the material masks used early within the pandemic to N95 or KN95 masks, which offer higher safety however are sometimes tougher to put on. Nonetheless, federal officers insist that the perfect masks is the one an individual will put on correctly and for the required interval. If an individual is extra seemingly to make use of a fabric masks often and doesn’t wish to maintain a better-quality masks on, she is healthier off utilizing the material masks, they level out.
- Dr. Rochelle Walensky, head of the Facilities for Illness Management and Prevention, is among the many officers taking warmth for not successfully speaking with the general public. Officers clearly have made missteps, however the change in covid variants surging via the nation has additionally referred to as for modifications in messaging, which has confused many individuals.
- Medicare’s announcement this week proposing to limit protection of Aduhelm, the controversial new drug to deal with Alzheimer’s illness, suggests officers overseeing the well being care program weren’t in sync with the FDA, which gave the drug restricted approval late final yr. Medicare can pay for the drug just for beneficiaries enrolled in medical research that Medicare approves. That may assist take a look at the effectiveness and security of the drug.
- The choice on Aduhelm, nonetheless, might result in inequity issues since these managing medical trials typically have issue recruiting a various clientele.
- The bounds on protection additionally might immediate Medicare to maneuver extra shortly on the decision by Well being and Human Companies Secretary Xavier Becerra to revise premiums for this yr. Medicare introduced within the fall that premiums would rise by practically 15% due to issues in regards to the annual price of Aduhelm, which on the time was priced at $56,000. The drugmaker slashed the value in half later.
Plus, for “additional credit score,” the panelists advocate their favourite well being coverage tales of the week that they suppose you must learn, too:
Julie Rovner: The AP’s “Flush With COVID-19 Help, Colleges Steer Funding to Sports activities,” by Collin Binkley and Ryan J. Foley
Joanne Kenen: The New York Instances’ “Covid Take a look at Misinformation Spikes Alongside With Unfold of Omicron,” by Davey Alba
Rachel Cohrs: KHN and Fortune’s “App Makes an attempt to Break Boundaries to Chapter for These in Medical Debt,” by Blake Farmer
Sarah Karlin-Smith: Stat’s “‘I’m Going to Show You Improper’: How a D.C. Energy Couple Used an ALS Prognosis to Create a Political Juggernaut,” by Lev Facher
To listen to all our podcasts, click on right here.
Submit a Story Tip
Supply By https://khn.org/information/article/podcast-khn-what-the-health-229-drug-prices-january-13-2022/